CLOVER HEALTH INVESTMENTS CO (CLOV)
US18914F1030 - Common Stock
Overall CLOV gets a fundamental rating of 2 out of 10. We evaluated CLOV against 117 industry peers in the Health Care Providers & Services industry. While CLOV seems to be doing ok healthwise, there are quite some concerns on its profitability. CLOV does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
CLOV had negative earnings in the past year.
In the past year CLOV has reported a negative cash flow from operations.
CLOV had negative earnings in each of the past 5 years.
CLOV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CLOV has a worse Return On Assets (-37.39%) than 84.48% of its industry peers.
CLOV has a Return On Equity of -74.50%. This is in the lower half of the industry: CLOV underperforms 71.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.39% | ||
| ROE | -74.5% | ||
| ROIC | N/A |
ROA(3y)-47.04%
ROA(5y)-28.38%
ROE(3y)-93.07%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CLOV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CLOV does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLOV has more shares outstanding than it did 1 year ago.
There is no outstanding debt for CLOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -1.77, we must say that CLOV is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.77, CLOV is not doing good in the industry: 77.59% of the companies in the same industry are doing better.
There is no outstanding debt for CLOV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.77 |
ROIC/WACCN/A
WACC9.29%
2.3 Liquidity
A Current Ratio of 1.64 indicates that CLOV should not have too much problems paying its short term obligations.
CLOV has a better Current ratio (1.64) than 66.38% of its industry peers.
CLOV has a Quick Ratio of 1.64. This is a normal value and indicates that CLOV is financially healthy and should not expect problems in meeting its short term obligations.
CLOV has a Quick ratio of 1.64. This is in the better half of the industry: CLOV outperforms 72.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.64 | ||
| Quick Ratio | 1.64 |
3. Growth
3.1 Past
CLOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.94%, which is quite impressive.
CLOV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -41.50%.
EPS 1Y (TTM)40.94%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q20%
Revenue 1Y (TTM)-41.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-43.23%
3.2 Future
CLOV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.57% yearly.
Based on estimates for the next years, CLOV will show a decrease in Revenue. The Revenue will decrease by -4.00% on average per year.
EPS Next Y48.84%
EPS Next 2Y24.11%
EPS Next 3Y17.97%
EPS Next 5Y18.57%
Revenue Next Year-36.38%
Revenue Next 2Y-18.36%
Revenue Next 3Y-11.2%
Revenue Next 5Y-4%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CLOV. In the last year negative earnings were reported.
Also next year CLOV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CLOV's earnings are expected to grow with 17.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.11%
EPS Next 3Y17.97%
5. Dividend
5.1 Amount
CLOV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CLOVER HEALTH INVESTMENTS CO
NASDAQ:CLOV (4/25/2024, 7:00:00 PM)
After market: 0.68 +0.01 (+1.49%)0.67
+0.02 (+3.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap331.84M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -37.39% | ||
| ROE | -74.5% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover3.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.64 | ||
| Quick Ratio | 1.64 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)40.94%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y48.84%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-41.5%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y